Nguyen
10-16-2023, 08:41 AM
This is a very hopeful news for Her2 Met patients!
A Phase I/II Trial of HER2 Vaccine–Primed Autologous T-Cell Infusions in Patients with Treatment Refractory HER2–Overexpressing Breast Cancer
https://aacrjournals.org/clincancerres/article-abstract/29/17/3362/728543/A-Phase-I-II-Trial-of-HER2-Vaccine-Primed?redirectedFrom=fulltext
Beyond Neoantigens: Antigens Derived from Tumor Drivers as Cancer Vaccine Targets
https://aacrjournals.org/clincancerres/article/29/17/3256/728547/Beyond-Neoantigens-Antigens-Derived-from-Tumor
A Phase I/II Trial of HER2 Vaccine–Primed Autologous T-Cell Infusions in Patients with Treatment Refractory HER2–Overexpressing Breast Cancer
https://aacrjournals.org/clincancerres/article-abstract/29/17/3362/728543/A-Phase-I-II-Trial-of-HER2-Vaccine-Primed?redirectedFrom=fulltext
Beyond Neoantigens: Antigens Derived from Tumor Drivers as Cancer Vaccine Targets
https://aacrjournals.org/clincancerres/article/29/17/3256/728547/Beyond-Neoantigens-Antigens-Derived-from-Tumor